Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CGEM |
---|---|---|
09:32 ET | 8607 | 17.15 |
09:33 ET | 1273 | 17.01 |
09:35 ET | 100 | 17.135 |
09:37 ET | 130 | 17.3 |
09:39 ET | 100 | 17.135 |
09:44 ET | 100 | 17.21 |
09:46 ET | 1000 | 17.243649 |
09:48 ET | 4911 | 17.31 |
09:50 ET | 2300 | 17.24 |
09:51 ET | 1511 | 17.4586 |
09:57 ET | 1178 | 17.39 |
10:00 ET | 445 | 17.32 |
10:02 ET | 483 | 17.26 |
10:04 ET | 100 | 17.26 |
10:06 ET | 7900 | 17.265 |
10:08 ET | 22850 | 17.135 |
10:09 ET | 300 | 17.135 |
10:11 ET | 719 | 17.12 |
10:13 ET | 12200 | 17.11 |
10:18 ET | 135 | 17.0963 |
10:20 ET | 5898 | 16.82 |
10:22 ET | 200 | 16.79 |
10:24 ET | 2766 | 16.75 |
10:26 ET | 5579 | 16.62 |
10:27 ET | 1205 | 16.7 |
10:29 ET | 11395 | 16.69 |
10:31 ET | 2906 | 16.6 |
10:33 ET | 100 | 16.54 |
10:36 ET | 100 | 16.55 |
10:38 ET | 300 | 16.52 |
10:40 ET | 2000 | 16.46 |
10:42 ET | 2986 | 16.39 |
10:44 ET | 3500 | 16.28 |
10:45 ET | 2335 | 16.34 |
10:47 ET | 1000 | 16.26 |
10:49 ET | 300 | 16.24 |
10:51 ET | 200 | 16.26 |
10:54 ET | 1493 | 16.25 |
10:56 ET | 500 | 16.25 |
10:58 ET | 4234 | 16.32 |
11:00 ET | 100 | 16.22 |
11:02 ET | 300 | 16.3338 |
11:03 ET | 1353 | 16.3262 |
11:05 ET | 2229 | 16.23 |
11:07 ET | 821 | 16.3388 |
11:09 ET | 400 | 16.33 |
11:12 ET | 100 | 16.29 |
11:16 ET | 552 | 16.29 |
11:18 ET | 1500 | 16.25 |
11:20 ET | 977 | 16.18 |
11:21 ET | 119 | 16.175 |
11:25 ET | 100 | 16.13 |
11:30 ET | 599 | 16.17 |
11:32 ET | 202 | 16.15 |
11:34 ET | 400 | 16.14 |
11:36 ET | 1792 | 16.14 |
11:38 ET | 100 | 16.16 |
11:41 ET | 1786 | 16.13 |
11:43 ET | 3590 | 16.305 |
11:50 ET | 2942 | 16.17 |
11:52 ET | 100 | 16.13 |
11:54 ET | 100 | 16.08 |
11:56 ET | 300 | 16.14 |
11:57 ET | 407 | 16.14 |
11:59 ET | 1200 | 16.19 |
12:01 ET | 200 | 16.21 |
12:06 ET | 1633 | 16.3 |
12:08 ET | 100 | 16.26 |
12:14 ET | 6908 | 16.27 |
12:17 ET | 100 | 16.16 |
12:19 ET | 300 | 16.135 |
12:21 ET | 233 | 16.135 |
12:24 ET | 100 | 16.08 |
12:26 ET | 8834 | 16.17 |
12:32 ET | 200 | 16.165 |
12:33 ET | 3142 | 16.29 |
12:35 ET | 300 | 16.34 |
12:37 ET | 202 | 16.395 |
12:39 ET | 714 | 16.395 |
12:42 ET | 617 | 16.395 |
12:44 ET | 400 | 16.39 |
12:48 ET | 210 | 16.39 |
12:50 ET | 600 | 16.3 |
12:51 ET | 1000 | 16.3201 |
12:53 ET | 100 | 16.21 |
12:55 ET | 995 | 16.32 |
12:57 ET | 1600 | 16.2393 |
01:00 ET | 500 | 16.2 |
01:06 ET | 2597 | 16.28 |
01:09 ET | 602 | 16.26 |
01:15 ET | 500 | 16.2 |
01:22 ET | 2108 | 16.11 |
01:24 ET | 607 | 16.14 |
01:26 ET | 500 | 16.17 |
01:31 ET | 100 | 16.16 |
01:33 ET | 357 | 16.15 |
01:36 ET | 1870 | 16.155 |
01:38 ET | 2778 | 16.22 |
01:40 ET | 100 | 16.1811 |
01:42 ET | 3100 | 16.24 |
01:45 ET | 100 | 16.17 |
01:47 ET | 100 | 16.195 |
01:49 ET | 400 | 16.195 |
01:51 ET | 900 | 16.155 |
01:54 ET | 1077 | 16.16 |
02:00 ET | 259 | 16.13 |
02:02 ET | 1600 | 16.19 |
02:03 ET | 100 | 16.19 |
02:12 ET | 1300 | 16.15 |
02:14 ET | 6320 | 16.13 |
02:16 ET | 832 | 16.12 |
02:18 ET | 357 | 16.12 |
02:20 ET | 2100 | 16.13 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Cullinan Therapeutics Inc | 1.0B | -5.6x | --- |
CARGO Therapeutics Inc | 1.0B | -6.1x | --- |
Nuvation Bio Inc | 1.0B | -1.3x | --- |
Rapport Therapeutics Inc | 983.9M | -14.4x | --- |
LENZ Therapeutics Inc | 983.2M | -3.9x | --- |
89Bio Inc | 1.1B | -3.2x | --- |
Cullinan Therapeutics, Inc., formerly Cullinan Oncology, Inc., is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. It has a portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its pipeline includes CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, and CLN-617. Its lead unpartnered program, CLN-619, is a humanized lgG1 monoclonal antibody (mAb) that binds to the stress induced ligands MICA and MICB (MICA/B), which are expressed on a variety of solid tumors and hematologic malignancies. CLN-978 is a novel, highly potent, half-life extended CD19xCD3 bispecific T cell engager construct. CLN-081/TAS6417 is a novel, orally available, covalent inhibitor of mutant epidermal growth factor receptor (EGFR). CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-418 is a B7H4 x 4-1BB bispecific immune activator.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.0B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 58.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.07 |
EPS | $-2.88 |
Book Value | $10.58 |
P/E Ratio | -5.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.